142 related articles for article (PubMed ID: 26634172)
21. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
[TBL] [Abstract][Full Text] [Related]
22. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
Yin H; Liao CG; Wang YQ; Li Z; Fan LL; Qian ML; Lu N
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):419-423. PubMed ID: 28635230
[No Abstract] [Full Text] [Related]
23. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B.
Mirkin BL; Clark SH; Zhang C
Cell Prolif; 2002 Apr; 35(2):105-15. PubMed ID: 11952645
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer.
Park S; Ha SY; Cho HY; Chung DH; Kim NR; Hong J; Cho EK
Lung Cancer; 2011 Apr; 72(1):100-7. PubMed ID: 20822827
[TBL] [Abstract][Full Text] [Related]
25. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.
Carr A; Mullet A; Mazorra Z; Vázquez AM; Alfonso M; Mesa C; Rengifo E; Pérez R; Fernández LE
Hybridoma; 2000 Jun; 19(3):241-7. PubMed ID: 10952412
[TBL] [Abstract][Full Text] [Related]
26. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
27. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer.
Hernández AM; Vázquez AM
Expert Rev Vaccines; 2015 Jan; 14(1):9-20. PubMed ID: 25420897
[TBL] [Abstract][Full Text] [Related]
28. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
29. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).
Suarez Pestana E; Greiser U; Sánchez B; Fernández LE; Lage A; Perez R; Böhmer FD
Br J Cancer; 1997; 75(2):213-20. PubMed ID: 9010029
[TBL] [Abstract][Full Text] [Related]
30. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
31. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
32. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities.
Rojas G; Pupo A; Gómez S; Krengel U; Moreno E
ACS Chem Biol; 2013 Feb; 8(2):376-86. PubMed ID: 23138862
[TBL] [Abstract][Full Text] [Related]
33. Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc.
Oliva JP; Valdés Z; Casacó A; Pimentel G; González J; Alvarez I; Osorio M; Velazco M; Figueroa M; Ortiz R; Escobar X; Orozco M; Cruz J; Franco S; Díaz M; Roque L; Carr A; Vázquez AM; Mateos C; Rubio MC; Pérez R; Fernández LE
Breast Cancer Res Treat; 2006 Mar; 96(2):115-21. PubMed ID: 16322892
[TBL] [Abstract][Full Text] [Related]
34. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
36. Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431.
Meuillet EJ; Mania-Farnell B; George D; Inokuchi JI; Bremer EG
Exp Cell Res; 2000 Apr; 256(1):74-82. PubMed ID: 10739654
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
38. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
39. Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Liu D; Huang Y; Zhang L; Liang DN; Li L
Oncol Lett; 2017 Oct; 14(4):3959-3966. PubMed ID: 28989534
[TBL] [Abstract][Full Text] [Related]
40. Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.
Palomo AG; Medinilla AL; Segatori V; Barroso MDC; Blanco R; Gabri MR; Pérez AC; Monzón KL
Oncotarget; 2018 May; 9(35):24069-24080. PubMed ID: 29844873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
